Monday 15th May 2017
The 2017 Annual NHS R&D Forum is to be held in association with the Health Research Authority on the 15th & 16th May at Hilton Deansgate, Manchester. It is a national event attracting around 500 delegates from provider and commissioning organisations who are driving and delivering research and innovation in health and care, and their R&D management teams.
Over the two days we will share good practice, discuss new policy and strategic insights, influence leaders, and debate and discuss hot topics; we will also ensure that our delegates meet, learn, network and share, regardless of role. Click here to see who is already booked to Exhibit and Sponsor at the 2017 Annual NHS R&D Forum
The aim of the event is therefore to bring the UK-wide health and care R&D community together and delegates include: R&D Leads, Directors, Managers, researchers and their teams, the Department of Health, NHS England, NIHR, Regulators, Charities, Academic Institutions, and Industry Sponsors and Partners.
There are a wide range of exhibition and sponsorship opportunities at the 2017 Annual NHS R&D Forum to allow you to connect with a large and diverse delegate group. Please click here for more information and click below to book your exhibition or sponsorship requirements.
To see who exhibited and sponsored at the 2016 Annual NHS R&D Forum click here
Book Exhibition and Sponsorship
Please click here to go to the online booking form
Business Development (led by Deborah O’Neil of NovaBiotics)
enables members to tap into the expertise of other, often larger, member companies, and to develop collaborative solutions to issues facing the sector as a whole.
Finance (led by Hugh Griffith of Nucana BioMed and Alida Capital)
has focussed on the availability of venture capital funding, but also looks at the provision of public sector support for our member companies. Also coordinates the Innovation Tutorial Programme.
HR (led by Fiona Beattie of Quintiles)
is valued by our members as a forum where HR and recruitment issues can be discussed in a collaborative space and pragmatic solutions developed with the secondary and tertiary education sectors.
Diagnostics and MedTech (led by Colin King of Axis-Shield)
tackles issues of particular relevance to diagnostics companies as they arise, and has also produced a summary of the opportunities for and barriers to growth in the diagnostics sub-sector of life sciences.
Innovation (led by David Pritchard, Axis-Shield, and Douglas Drysdale, HGF)
covers a variety of issues including ownership and commercialisation of University IP through to tax incentives for innovation.
Regulatory and Quality (led by Andrew Waddell of TMQA)
is a forum for SLA members to learn about the regulatory and compliance issues affecting product development and commercialisation, and make representations to regulators and Government as needed. Currently, SLA representatives sit on three MHRA panels.
Digital Health (led by Campbell Grant of Sitekit Solutions)
enables collaboration between member companies in this expanding area, covering personal health software development, telehealthcare systems implementation, health data mining, and life sciences risk analysis systems; and works to help grow companies in this part of the life sciences sector
Cell Therapy (led by Jim Reid of Sistemic)
aims to be a strong industry voice for the stem cell community in Scotland; and makes investors and Government aware of the timeline and costs associated with developing an industry in the sector.
Medicines (led by Tom Stratford of ProStrakan)
works closely with the Scottish Government as it sets up a new partnership between medicine development companies in Scotland and the NHS
Directors Forum (led by Alan Walker of Ryboquin)
provides a space for both Executive and Non-Executive Directors of member companies to meet and exchange views on the sector in Scotland, and to be briefed on hot topics.
Manufacturing (led by John Scott of LifeScan)
aims to highlight opportunities for investment in, and benefits of automation, along with pitfalls, challenges and best practice.
Precision Medicine (led by David Bunton of Biopta)
is focused on getting the most from the recent government investment in the Stratified Medicines Innovation Centre. It aims to bring together SMS-IC with Scottish life sciences companies, and to facilitate cross-company collaborations.